Teva Pharmaceutical Industries ( TEVA ) shares are trading lower Wednesday on the heels of the company’s fourth-quarter financial results. Here’s what you need to know.

What To Know: Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of 71 cents per share, beating estimates of 70 cents per share.

“Focusing on rigorous execution of our Pivot to Growth strategy throughout the year, we continued to achieve important milestones in each of its four pillars, including surpassing the outlook for our key innovative products, growing our generics business across all segments, and accelerating our early-stage innovative pipeline, including the positive Phase 2b results for our duvakitug (anti-Tl1A) asset,” said Richard Francis, president and CEO of Teva Pharmaceutical.

“These results pave the way for pivotal trials in Crohn’s disease and ulcerative colitis, as well as, potentially, other Immunological and fibrotic indications beyond, in collaboration with our partner, Sanofi.”

Check This Out: Danaher Q4: EPS Miss Expectations Amid Diagnostics Segment Lag

Outlook: Teva Pharmaceutical expects full-year 2025 revenue to be in the range of $16.8 billion to $17.4 billion versus estimates of $17.05 billion. The company expects full-year adjusted earnings to be between $2.35 and $2.65 per share versus estimates of $2.79 per share.

“In 2025, we anticipate further progress in our key innovative growth drivers, while also executing on our complex generics and biosimilars business, supported by new product launches. We are also excited to advance to Phase 3 trials for our duvakitug (anti-TL1A) asset,” Francis said.

The company’s earnings guidance appears to be weighing on shares. Management is currently discussing the quarter on a conference call that kicked off at 8 a.m. ET.

TEVA Price Action: Teva Pharmaceutical shares were down 8.78% at $19.64 at the time of publication, according to Benzinga Pro.